皮内阻滞联合臭氧治疗带状疱疹瘙痒症1例

2019-09-12 刘秀金 贾和平 中国疼痛医学杂志

病人,男性,23岁,主因左肩关节活动受限6周余入院。病人左肩关节习惯性脱位于骨科行左肩关节囊成形修复术,术后6周因左肩关节活动受限需进一步康复治疗在我科(疼痛康复科)住院治疗,入院第三天上午自觉左大腿前侧发痒,暴露左大腿后发现大腿前侧出现片状红斑,红斑上可见簇状粟粒大小的水疱,有痛觉超敏,诊断带状疱疹,给予静点阿昔洛韦注射液和外用喷昔洛韦软膏抗病毒治疗,同时给予B族维生素营养神经治疗,病人左大腿内

水痘-带状疱疹病毒侵犯感觉神经后引起疼痛、甚至剧烈的瘙痒。文献报道带状疱疹顽固性瘙痒多见于带状疱疹的亚急性期及慢性期,带状疱疹后瘙痒药物治疗效果差时,目前采用的治疗方法如脉冲射频治疗、神经电刺激、硬膜外镇痛药物治疗,本研究在临床工作中遇到一例带状疱疹病人在急性期结痂时出现顽固性瘙痒,瘙痒评分采用视觉模拟评分法(visual analogue scale,VAS)达到10分,严重干扰病人的生活及睡眠,为解决病人的痛苦,提高病人的生活质量,给予抗病毒、营养神经、神经修复调节药物、抗组胺药物、钙离子通道调节剂等多种药物治疗无效,而给予皮内阻滞联合臭氧治疗后取得良好效果,现报道如下。
 
1.方法
 
1.1一般资料
 
病人,男性,23岁,主因左肩关节活动受限6周余入院。病人左肩关节习惯性脱位于骨科行左肩关节囊成形修复术,术后6周因左肩关节活动受限需进一步康复治疗在我科(疼痛康复科)住院治疗,入院第三天上午自觉左大腿前侧发痒,暴露左大腿后发现大腿前侧出现片状红斑,红斑上可见簇状粟粒大小的水疱,有痛觉超敏,诊断带状疱疹,给予静点阿昔洛韦注射液和外用喷昔洛韦软膏抗病毒治疗,同时给予B族维生素营养神经治疗,病人左大腿内侧及外侧相继出现红斑及水疱,病人抗病毒及营养神经治疗1周后疱疹结痂,但病人诉大腿内侧、前侧及外侧剧烈瘙痒感,外侧发痒明显,即使抓破瘙痒皮肤仍不能缓解症状,发痒部位有轻度触痛,夜间睡眠1~3小时左右,瘙痒VAS评分10分,疼痛VAS评分2分。
 
1.2治疗
 
根据病人痒痛的症状,以发痒为主症,先后口服马来酸氯苯那敏片、氯雷他定片后夜间能入睡,但晨起时发现大腿皮肤被抓破,然后先后给予口服加巴喷丁胶囊、普瑞巴林胶囊及静点牛痘疫苗致炎兔皮提取物注射液后发痒症状无缓解倾向。无出血倾向、凝血功能异常,由病人签署知情同意书,安排腰椎椎旁阻滞后痒痛仍无丝毫缓解,疱疹结痂脱落后,安排疱疹发痒部位行皮内阻滞联合臭氧治疗3次,间隔1周。
 
皮内阻滞联合臭氧治疗:病人取仰卧位,暴露左大腿内侧、前侧及外侧,触摸左大腿疱疹发痒区域为阻滞点,常规消毒,戴无菌手套,铺无菌洞巾,以10ml注射器接1ml的针头为穿刺针,根据发痒皮肤面积抽取消炎镇痛液(2%利多卡因3ml+地塞米松注射液2mg+0.9%生理盐水25ml),在阻滞区域皮内注射1.5 cm直径的皮丘,皮丘间隔1 cm,然后根据发痒面积再抽取20μg/ml臭氧在阻滞区域皮内注射,共30ml臭氧,注毕,拔针,常规消毒,敷料覆盖,绷带包扎,病人无不适,平卧20min后安返病房。
 
2.结果
 
病人阻滞治疗1次后瘙痒的程度减轻,发痒的面积缩小,瘙痒VAS评分6分,疼痛VAS评分1分,病人阻滞治疗2次后瘙痒VAS评分3分,疼痛VAS评分0分,阻滞治疗3次后瘙痒VAS评分0分,疼痛VAS评分0分,随访1、2、3月无复发,睡眠正常。无并发症及不良反应发生。
 
3.讨论
 
临床观察带状疱疹急性期引起顽固性瘙痒少见,其发生率国内外鲜见报道,Ozdemir等研究的178例带状疱疹病人中有20例合并瘙痒,患病前有2例,患病中有16例,治愈后有2例,研究中96%的带状疱疹病人瘙痒部位发现了受损的外周神经,这也证实了带状疱疹引起的瘙痒是神经病理性瘙痒,目前这种瘙痒临床均无有效的治疗方案,治疗瘙痒的抗组胺药物对神经病理性瘙痒的疗效不明显。辣椒辣素和局部麻醉药如利多卡因常用于神经病理性瘙痒。
 
Kopecky等采用局麻药物利多卡因和丙胺卡因的混合物治疗创面瘙痒,发现其能明显降低瘙痒程度和发作频率。2013年中国医师协会皮肤科医师分会,《中国带状疱疹治疗指南》专家组指出辣椒碱软膏通过影响疼痛,传递因子P物质的释放合成与储存,从而实现镇痛和止痒的功效。但因我院药房无此药未能观察到此药的疗效。
 
带状疱疹引起的瘙痒原因可能是由于病毒通过感觉轴突转移到皮肤,从一个细胞传播到另一个细胞,穿透表皮,在这种病理条件下,皮肤细胞中的角质细胞、上皮细胞及内皮细胞分泌胺类物质、5-羟色胺、神经肽、前列腺素等多种内源性致痒物质,刺激肥大细胞释放组胺或直接刺激皮肤C类纤维末梢诱发皮肤瘙痒,而瘙痒又引起瘙抓反射,通过搔抓来缓解瘙痒,但搔抓又增加炎性介质(组胺、5-羟色胺、前列腺素等)释放和刺激神经C纤维,导致“瘙痒-搔抓-瘙痒”的恶性循环,打断这种恶性循环的药物或治疗是缓解带状疱疹瘙痒的新切入点。
 
皮内阻滞联合臭氧治疗带状疱疹瘙痒症,它能打断“瘙痒-搔抓-瘙痒”的恶性循环,首先在瘙痒区域行皮内阻滞,皮内阻滞中的利多卡因应用于皮内组织后通过抑制肥大细胞与神经纤维之间的联系而达到止痒,同时利多卡因作用于神经末梢,阻断神经的传导功能,使局部组织或相应神经支配区域产生暂时性的、可逆性感觉丧失,进而减轻疼痛和瘙痒,这是阻断恶性循环的“瘙痒-搔抓”;地塞米松注射液作为糖皮质激素制剂,它能降低炎性物质生成、抑制受损感觉神经异常放电和炎性介质的释放而阻断“搔抓-瘙痒”。
 
研究表明带状疱疹病人血清中的组胺、5-羟色胺、神经肽(神经肽Y、P物质)、前列腺素、去甲肾上腺素这些化学物质明显升高,而这些物质又致痒;医用臭氧作用于神经末梢可抑制病变部位前列腺素、缓激肽这些致痒、致痛化学物质及致痒、致痛复合物的合成与释放,从而发挥止痒、镇痛的作用,同时皮内阻滞缓解了直接注射低浓度臭氧引起的疼痛,从而减轻治疗给病人带来的痛苦。故皮内阻滞联合臭氧治疗顽固性带状疱疹瘙痒症可作为一种试用方法,这种方法也需要在以后工作中进一步实践及完善。
 
原始出处:

刘秀金,贾和平.皮内阻滞联合臭氧治疗带状疱疹瘙痒症1例[J].中国疼痛医学杂志,2018(09):716-717+720.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1800191, encodeId=2f081800191d6, content=<a href='/topic/show?id=fafbe1946c8' target=_blank style='color:#2F92EE;'>#皮内阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71946, encryptionId=fafbe1946c8, topicName=皮内阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Fri Jul 31 12:05:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302576, encodeId=450d13025e626, content=<a href='/topic/show?id=b541e1219dc' target=_blank style='color:#2F92EE;'>#瘙痒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71219, encryptionId=b541e1219dc, topicName=瘙痒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402909, encodeId=187a1402909fc, content=<a href='/topic/show?id=6103e12204a' target=_blank style='color:#2F92EE;'>#瘙痒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71220, encryptionId=6103e12204a, topicName=瘙痒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6f82431450, createdName=lvygwyt2782, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406933, encodeId=4345140693303, content=<a href='/topic/show?id=f8d88639461' target=_blank style='color:#2F92EE;'>#臭氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86394, encryptionId=f8d88639461, topicName=臭氧)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=ibXWWwSRHML00iboFvP8drcw&s=100, createdBy=4e292579924, createdName=xuqianhua, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580439, encodeId=504a158043928, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1800191, encodeId=2f081800191d6, content=<a href='/topic/show?id=fafbe1946c8' target=_blank style='color:#2F92EE;'>#皮内阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71946, encryptionId=fafbe1946c8, topicName=皮内阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Fri Jul 31 12:05:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302576, encodeId=450d13025e626, content=<a href='/topic/show?id=b541e1219dc' target=_blank style='color:#2F92EE;'>#瘙痒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71219, encryptionId=b541e1219dc, topicName=瘙痒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402909, encodeId=187a1402909fc, content=<a href='/topic/show?id=6103e12204a' target=_blank style='color:#2F92EE;'>#瘙痒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71220, encryptionId=6103e12204a, topicName=瘙痒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6f82431450, createdName=lvygwyt2782, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406933, encodeId=4345140693303, content=<a href='/topic/show?id=f8d88639461' target=_blank style='color:#2F92EE;'>#臭氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86394, encryptionId=f8d88639461, topicName=臭氧)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=ibXWWwSRHML00iboFvP8drcw&s=100, createdBy=4e292579924, createdName=xuqianhua, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580439, encodeId=504a158043928, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=)]
    2019-09-14 listen318
  3. [GetPortalCommentsPageByObjectIdResponse(id=1800191, encodeId=2f081800191d6, content=<a href='/topic/show?id=fafbe1946c8' target=_blank style='color:#2F92EE;'>#皮内阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71946, encryptionId=fafbe1946c8, topicName=皮内阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Fri Jul 31 12:05:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302576, encodeId=450d13025e626, content=<a href='/topic/show?id=b541e1219dc' target=_blank style='color:#2F92EE;'>#瘙痒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71219, encryptionId=b541e1219dc, topicName=瘙痒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402909, encodeId=187a1402909fc, content=<a href='/topic/show?id=6103e12204a' target=_blank style='color:#2F92EE;'>#瘙痒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71220, encryptionId=6103e12204a, topicName=瘙痒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6f82431450, createdName=lvygwyt2782, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406933, encodeId=4345140693303, content=<a href='/topic/show?id=f8d88639461' target=_blank style='color:#2F92EE;'>#臭氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86394, encryptionId=f8d88639461, topicName=臭氧)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=ibXWWwSRHML00iboFvP8drcw&s=100, createdBy=4e292579924, createdName=xuqianhua, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580439, encodeId=504a158043928, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1800191, encodeId=2f081800191d6, content=<a href='/topic/show?id=fafbe1946c8' target=_blank style='color:#2F92EE;'>#皮内阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71946, encryptionId=fafbe1946c8, topicName=皮内阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Fri Jul 31 12:05:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302576, encodeId=450d13025e626, content=<a href='/topic/show?id=b541e1219dc' target=_blank style='color:#2F92EE;'>#瘙痒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71219, encryptionId=b541e1219dc, topicName=瘙痒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402909, encodeId=187a1402909fc, content=<a href='/topic/show?id=6103e12204a' target=_blank style='color:#2F92EE;'>#瘙痒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71220, encryptionId=6103e12204a, topicName=瘙痒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6f82431450, createdName=lvygwyt2782, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406933, encodeId=4345140693303, content=<a href='/topic/show?id=f8d88639461' target=_blank style='color:#2F92EE;'>#臭氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86394, encryptionId=f8d88639461, topicName=臭氧)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=ibXWWwSRHML00iboFvP8drcw&s=100, createdBy=4e292579924, createdName=xuqianhua, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580439, encodeId=504a158043928, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=)]
    2019-09-14 xuqianhua
  5. [GetPortalCommentsPageByObjectIdResponse(id=1800191, encodeId=2f081800191d6, content=<a href='/topic/show?id=fafbe1946c8' target=_blank style='color:#2F92EE;'>#皮内阻滞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71946, encryptionId=fafbe1946c8, topicName=皮内阻滞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Fri Jul 31 12:05:00 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302576, encodeId=450d13025e626, content=<a href='/topic/show?id=b541e1219dc' target=_blank style='color:#2F92EE;'>#瘙痒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71219, encryptionId=b541e1219dc, topicName=瘙痒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d17305, createdName=listen318, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402909, encodeId=187a1402909fc, content=<a href='/topic/show?id=6103e12204a' target=_blank style='color:#2F92EE;'>#瘙痒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71220, encryptionId=6103e12204a, topicName=瘙痒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c6f82431450, createdName=lvygwyt2782, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406933, encodeId=4345140693303, content=<a href='/topic/show?id=f8d88639461' target=_blank style='color:#2F92EE;'>#臭氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86394, encryptionId=f8d88639461, topicName=臭氧)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=ibXWWwSRHML00iboFvP8drcw&s=100, createdBy=4e292579924, createdName=xuqianhua, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580439, encodeId=504a158043928, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Sat Sep 14 08:05:00 CST 2019, time=2019-09-14, status=1, ipAttribution=)]